GLUD1

Across TCGA pan-cancer cohorts, GLUD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GLUD1 data layer compared with 30 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher GLUD1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GLUD1 expression acts as an unfavorable survival marker, although some lineages such as OV and PDAC show a favorable association.

OV, CCRCC, and HNSC are the cancer types where GLUD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.942	0.548	.003	12	view →
CCRCC	DFS	Median	II,III,IV	0.455	0.781	.013	8	view →
HNSC	DFS	Median	II,III,IV	0.559	0.751	.028	3	view →
PDAC	OS	Quartile	All	0.904	0.715	.023	2	view →
LSCC	DFS	Quartile	III,IV	1.000	0.547	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GLUD1–OV (DFS)

Open the OV breakdown →